Gilead Sciences to Release Second Quarter 2005 Financial Results on Tuesday, July 19, 2005; Conference Call and Webcast to Follow

Back

FOSTER CITY, Calif.--(BUSINESS WIRE)--July 12, 2005--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its second quarter 2005 financial results will be released on Tuesday, July 19, 2005, after the close of the U.S. Financial Markets. At 4:30 p.m. Eastern Time, Gilead will host a conference call and live webcast on the company's internet site. The call will be led by John Martin, PhD, President and Chief Executive Officer; John Milligan, PhD, Executive Vice President and Chief Financial Officer; and Kevin Young, Executive Vice President, Commercial Operations. Gilead management will discuss the company's second quarter results and other business results.

To access the webcast via the internet, log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call 1-800-510-9661 (U.S.) or 1-617-614-3452 (international) and dial the participant passcode 63001554 to access the call. Telephone replay is available approximately two hours after the call through 6:30 p.m. Eastern Time, July 21, 2005. To access, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 33269393. The webcast will be archived on www.gilead.com for one year.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT: Gilead Sciences, Inc. Susan Hubbard, 650-522-5715 (Investor Relations) SOURCE: Gilead Sciences, Inc.